A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population

International Journal of Rheumatic Diseases

Volumn 21, Issue 8, 2018, Pages 1581-1590

  Jones, Graeme ^a   Hall, Stephen ^b   Bird, Paul ^c   Littlejohn, Geoff ^d   Tymms, Kathleen ^e   Youssef, Peter ^f   Chung, Eric ^g   Barrett, Rina ^h   Button, Peter ^h  

^a UNIVERSITY OF TASMANIA   (Australia)

^b CABRINI HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g Prospection Pty Ltd   (Australia)

^h Roche Products Pty Limited   (Australia)

Author keywords

biologics; DMARD; glucocorticoids; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; AUSTRALIAN; CONTROLLED STUDY; DEMOGRAPHY; DESCRIPTIVE RESEARCH; DOCUMENTATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; AUSTRALIA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; PUBLIC HEALTH; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRALIA; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85037333640     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.13243     Document Type: Article

References (31)

1. Smolen JS, Landewe R, Breedveld FC et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73, 492–509
2. Greenberg JD, Reed G, Decktor D et al. (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71, 1134–42
3. Choy EH, Smith C, Dore CJ, Scott DL (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 44, 1414–21
4. Geborek P, Crnkic M, Petersson IF, Saxne T (2002) Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 61, 793–8
5. Hetland ML, Christensen IJ, Tarp U et al. (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62, 22–32
6. Salaffi F, Carotti M, Di Carlo M, Farah S (2015) Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis. J Clin Rheumatol 21, 419–25
7. Gabay C, Riek M, Hetland ML et al. (2016) Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis 75, 1336–42
8. Hishitani Y, Ogata A, Shima Y et al. (2013) Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol 42, 253–9
9. Leffers HC, Ostergaard M, Glintborg B et al. (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70, 1216–22
10. Neovius M, Arkema EV, Olsson H et al. (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74, 354–60
11. Tanaka T, Hishitani Y, Ogata A (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics 8, 141–53
12. Rotar Z, Hocevar A, Rebolj Kodre A, Praprotnik S, Tomsic M (2015) Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clin Rheumatol 34, 1787–93
13. Roberts L, Tymms K, de Jager J et al. (2013) A longitudinal study of the clinical effects of conventional and biologic disease modifying anti-rheumatic drugs in Australian rheumatology practice. Australian Rheumatology Association, 54th Annual Scientific Meeting; 18–22 May Perth, WA, Australia
14. Gorter SL, Bijlsma JW, Cutolo M et al. (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis [Review] 69, 1010–4
15. Smolen JS, Landewe R, Breedveld FC et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69, 964–75
16. Duru N, van der Goes MC, Jacobs JW et al. (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72, 1905–13
17. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ (2009) Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 68, 1833–8
18. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR (2010) Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 49, 82–90
19. Seror R, Dougados M, Gossec L (2009) Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 27, 807–13
20. Naumann L, Huscher D, Detert J, Spengler M, Burmester GR, Buttgereit F (2009) Anti-tumour necrosis factor alpha therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment. Ann Rheum Dis 68, 1934–6
21. Nilsson AC, Christensen AF, Junker P, Lindegaard HM (2011) Tumour necrosis factor-alpha inhibitors are glucocorticoid-sparing in rheumatoid arthritis. Dan Med Bull 58, A4257
22. Fortunet C, Pers YM, Lambert J et al. (2015) Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology (Oxford) 54, 672–7
23. Saraux A, Rouanet S, Flipo RM et al. (2016) Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study. Clin Exp Rheumatol 34, 303–10
24. Australian Government. Rheumatoid arthritis. [Web Page] [cited December 2016]; Available from: https://www.humanservices.gov.au/health-professionals/enablers/rheumatoid-arthritis#a2. Accessed September 2017
25. Australian Government. Schedule of Pharmaceutical Benefits[Cited December 2014]. Available from http://www.pbs.gov.au/publication/schedule/2014/12/2014-12-01-general-schedule.pdf. In: Department of Health, editor. Accessed September 2017
26. Johnston SS, McMorrow D, Farr AM, Juneau P (2015) Comparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologic. Rheumatol Ther 2, 59–71
27. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70, 583–9
28. Neubauer S, Cifaldi M, Mittendorf T, Ganguli A, Wolff M, Zeidler J (2014) Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Econ Rev 4, 32
29. Jorgensen TS, Kristensen LE, Christensen R et al. (2015) Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology (Oxford) 54, 2156–65
30. Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA (2016) Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev 11, CD012437
31. Weinblatt ME, Schiff M, Valente R et al. (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65, 28–38